CAMBRIDGE, Mass. , Oct. 12, 2023 /PRNewswire/ -- Alopexx, Inc., a clinical stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal and parasitic infections, today announced that Daniel Vlock, MD, Co-Founder, Chief Executive Officer and Chairman of the Board of Alopexx, is scheduled to present at IDWeek's 2023's New Antimicrobials in the Pipeline symposium being held October 11-15, 2023 in Boston, MA.
CAMBRIDGE, Mass., Oct. 11, 2023 /PRNewswire/ -- Alopexx, Inc., a clinical stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal and parasitic infections, today announced that Colette Cywes-Bentley, Ph.D., Assistant Professor of Medicine at Brigham and Women's Hospital, is scheduled to present pre-clinical data at IDWeek 2023's Microbial Pathogenesis of Alzheimer's Disease symposium being held October 11-15, 2023 in Boston, MA.